pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,215 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT915Endpoints708BioPharma Dive269onclive165BioSpace155Fierce Biotech147globenewswire health73raps
therapy area
allOncology5406Rare Disease1113Cardiology985Hematology871Immunology832Pulmonology703Psychiatry & CNS
  • Merck KGaA to receive up to €40 million in US tariff refunds for life science business through 2026
    Merck KGaA announced that it expects to receive tariff refunds for its life‑science division after a US Supreme Court ruling. The company estimates the refunds will total roughly €40 million and w…
    Endpoints · 4d agoRegulatoryPositive↗ source
  • Novo Nordisk board members disclose share vesting transactions
    Novo Nordisk issued a regulatory announcement on 6 August 2026 detailing share transactions by its board members, executives and related persons, as required by EU market abuse regulation. The fil…
    globenewswire health · 5d agoRegulatoryNeutral↗ source
← prev
page 3 of 49
next →
55
fda recalls35
fda press24
fda medwatch23
643
Vaccines612
Endocrinology & Metabolism319
Ophthalmology313
Pain307
Infectious Disease300
  • Centene reports strong enrollment growth but modest scale for its ICHRA offering
    Centene's chief executive Sarah London said the company's individual coverage health reimbursement arrangement (ICHRA) business is experiencing a strong enrollment growth rate, though the total num…
    Endpoints · 4d agoEarningsPositive↗ source
  • InstallatørGruppen reports insider share transaction involving board members' associate
    InstallatørGruppen A/S has filed a Market Abuse Regulation (EU) No. 596/2014 notification under article 19, disclosing a recent share transaction. The transaction was executed by Absalon Holdings…
    globenewswire health · 5d agoRegulatoryNeutral↗ source
  • InstallatørGruppen reports share transaction by board linked entity Absalon Holdings
    InstallatørGruppen A/S filed a notification under the EU Market Abuse Regulation, article 19, to disclose a share transaction involving a person discharging managerial responsibilities and their cl…
    globenewswire health · 5d agoRegulatoryNeutral↗ source
  • Lilly beats forecasts while Novo Nordisk misses sales and trial targets
    Eli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…
    BioPharma Dive · 5d agoEarningsNeutral↗ source
  • Eli Lilly Q2 revenue hits $23 billion, topping forecasts as tirzepatide drives two-thirds of sales
    Eli Lilly reported second-quarter revenue of $23 billion, roughly $3 billion above analysts' estimates. Tirzepatide contributed about 64% of the total, highlighting its central role in the company…
    Endpoints · 5d agoEarningsPositive↗ source
  • FDA approves Takeda's orexin drug for narcolepsy type 1
    Takeda has received FDA approval for its orexin agonist intended to treat narcolepsy type 1. The decision ends a closely watched commercial race to bring an orexin-based therapy to market. With a…
    Endpoints · 5d agoApprovalPositive↗ source
  • Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseases
    Attovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…
    BioPharma Dive · 5d agoDealPositive↗ source
  • Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mount
    Novo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure. He highlighted recent disappointments in the company's pipe…
    Endpoints · 5d agoDealNeutral↗ source
  • Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debut
    Attovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million. The funds will support the development of three I&I dru…
    Endpoints · 5d agoDealPositive↗ source
  • Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecasts
    Gilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…
    Endpoints · 6d agoEarningsPositive↗ source
  • Arrowhead Pharma to pay $215 million for PRV in its latest acquisition
    Arrowhead Pharmaceuticals disclosed in an SEC filing that it will acquire PRV for $215 million, marking the highest price tag for a deal this year. The purchase aligns with Arrowhead's strategy of…
    Endpoints · 5d agoDealNeutral↗ source
  • Expedition Therapeutics raises $115M Series B for China-sourced COPD candidate
    Expedition Therapeutics, a US biotech, announced a $115 million Series B financing round. The capital will be used to advance its COPD drug candidate that is being developed from a China-sourced p…
    Endpoints · 5d agoDealPositive↗ source
  • Expedition Therapeutics secures $115M Series B to advance China-origin COPD drug
    Expedition Therapeutics, a biotech that licenses drugs from Chinese firms, announced a $115 million Series B financing that will fund mid-stage testing of its experimental COPD candidate. The fund…
    BioPharma Dive · 5d agoDealPositive↗ source
  • WuXi AppTec posts six-month revenue higher than Lonza for first time
    WuXi AppTec, a Chinese contract manufacturing organization, has reported that its revenue over the most recent six-month period exceeded that of Swiss CDMO Lonza for the first time. The increase c…
    Endpoints · 5d agoPositive↗ source
  • Gilead reports modest sales rise but analysts question future growth beyond HIV drugs
    Gilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…
    BioPharma Dive · 5d agoEarningsNeutral↗ source
  • AstraZeneca and Bristol Myers Squibb abandon merger talks
    Reuters reported that AstraZeneca and Bristol Myers Squibb have ended discussions about a possible merger and will not pursue a deal. The collapse of the talks removes a potential consolidation th…
    Endpoints · 5d agoDealNegative↗ source
  • Senate confirms Erica Schwartz as new CDC director
    The U.S. Senate voted 51 to 44 on Wednesday to confirm Erica Schwartz as the next director of the Centers for Disease Control and Prevention. Schwartz, a former deputy surgeon general and a vetera…
    Endpoints · 5d agoRegulatoryNeutral↗ source
  • Atossa Therapeutics CEO Steven Quay likely to become NIAID director
    Steven Quay, founder and CEO of Atossa Therapeutics, is reported to be the likely choice for director of NIH's National Institute of Allergy and Infectious Diseases. The report notes his backgroun…
    Endpoints · 5d agoNeutral↗ source
  • Fujifilm Biotechnologies appoints COO Maja Pedersen as new president after Lars Petersen steps down
    Fujifilm Biotechnologies announced that its chief executive officer and president, Lars Petersen, has stepped down effective immediately. The company said the transition will be seamless as the cur…
    Endpoints · 5d agoNeutral↗ source
  • AL Sydbank discloses share transactions by managers and related persons under MAR
    AL Sydbank issued a company announcement (No 41/2026) on 5 August 2026, informing the market of share transactions carried out by its managers and persons closely associated with them. The disclos…
    globenewswire health · 5d agoRegulatoryNeutral↗ source
  • Alphabet reshuffles AI leadership as DeepMind CEO steps down to become chief scientist
    Alphabet announced a reorganization of its artificial intelligence leadership. Demis Hassabis will leave his role as chief executive of Google DeepMind and take on the position of chief scientist f…
    Endpoints · 5d agoNeutral↗ source
  • Danske Bank corrects placement of English PDF in transaction disclosure
    The bank originally posted a notice that attached both the Danish and English PDF files to the Danish version of its website. A correction has now moved the English PDF to the English version of th…
    globenewswire health · 5d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website link, moves English PDF to English page for shareholding report
    A correction notice was issued for Danske Bank A/S regarding the placement of an English PDF document on its website. The original announcement had both Danish and English PDFs attached under the…
    globenewswire health · 5d agoRegulatoryNeutral↗ source